Objective-To determine whether CX 3 CR1 ϩ bone marrow cells have the capacity for smooth muscle cell (SMC) differentiation. Methods and Results-CX 3 CR1 ϩ and CX 3 CR1 Ϫ cells were isolated from marrow of CX 3 CR1 transgenic mice and cultured in SMC differentiation media. Phenotypic and functional analyses showed only CX 3 CR1 ϩ bone marrow cells exhibit colony cell outgrowth with SMC-specific protein expression, calcium signaling, and contraction responses similar to mature SMC. Conclusion-CX 3 CR1 marks a bone marrow cells population that enriches for progenitors with capacity to differentiate in vitro into SMC-like cells. (Arterioscler Thromb Vasc Biol. 2010;30:533-535.)
I n arterial injury bone marrow cells (BMC), resident smooth muscle cells (SMC) and adventitial progenitors have been shown to contribute to neointimal SMC. 1 We recently showed that human smooth muscle outgrowth cells (SOC) were positive for the myeloid marker CD14 and retained CX 3 CR1 in extended clonal culture in vitro. 2 CX 3 CR1 is not expressed in the normal vessel wall but is significantly upregulated in neointimal SMC of injured vessel wall. Because CX 3 CR1 in marrow signifies mainly monocytic cells in mice, we hypothesized that CX 3 CR1 identifies a pool of cells that contains SMC progenitors.
To investigate the possibility that CX 3 CR1 marks a BM population that can be coaxed along a SMC differentiation path, we examined cultured CX 3 CR1 ϩ and CX 3 CR1 Ϫ BMC isolated from CX 3 CR1-gfp transgenic mice (animals were obtained from The European Mouse Mutant Archive, Orleans, France). Prototypical SMC expression characteristics and functionalities were assessed by SMC-specific mRNA and protein analysis and depolarization/contraction responses to SMC agonists. Finally, purified CX 3 CR1 ϩ BMC adoptively transferred into the injured vasculature were examined for in vivo differentiation into SM-like cells.
Materials and Methods
CX 3 CR1 ϩ and CX 3 CR1 Ϫ cells were isolated from marrow of CX 3 CR1 gfp/ϩ transgenic mice and cultured in SMC differentiation media. Phenotypic and functional analyses (SMC-specific antibody staining, calcium signaling, and contraction responses) were performed on outgrowth cells. Detailed methods can be found in supplemental materials (http://atvb.ahajournals.org). Figure 1A , Figure IA ). The proportion of GFP-positive cells in the bone marrow was Ϸ10% ( Figure I , please see http://atvb.ahajournals.org). GFP Ϫ fraction of BMC after initial attachment failed to grow in the media and after 1 to 2 weeks. No live GFP Ϫ cells were detected ( Figure 1A , Figure IB) . In contrast, cells from GFP ϩ fraction were able to form colonies of SM-like cells (3.4Ϯ2.0 SMC-like colonies per 10 million GFP ϩ cells, BMC seeded) within 6 weeks of initial seeding ( Figure 1B) . These cells were further examined for SMC characteristics. Figure II) . A distinguishing marker for CX 3 CR1 ϩ BMC was CD115, which marks the mononuclear phagocyte system in the mouse. 4 The GFP ϩ BMC also expressed CD11b and Gr-1 similar to that of GFP Ϫ group, but at a lower intensity. Both groups were negative for SMC markers, a-SMA, MHC, or calponin, before culture.
Results

BM-Derived CX 3 CR1 ؉ Cells Exhibit SMC-Like Differentiation In Vitro
CX 3 CR1 ϩ (GFP ϩ ) and CX 3 CR1 Ϫ (GFP Ϫ ) BMC were iso- lated from CX 3 CR1 gfp/ϩ mice 3 (
Analysis of BMC and SM Outgrowth Cells
Because GFP Ϫ BM did not possess the ability to form outgrowth, we performed all further studies on cells derived from GFP ϩ population. Transcripts for SMC-specific markers (␣SM-actin, calponin, MHC, and PDGF-bb receptor) were detected early in culture and increasingly expressed in outgrowth cells ( Figure 1C ). Morphologically, 2 distinct populations were observed in late outgrowth culture ( Figure 1D ). One cell group had a much larger size (150 -300 m in diameter), whereas the other cells were smaller (Ͻ100 m in diameter). Antibodies against ␣SM-actin, MHC, and calponin preferentially marked the larger cells and showed a myofilamentous pattern ( Figure 1D ), whereas F4/80 ( Figure III) was positive in the smaller cells, indicating SMC and macrophage immunoreactivity. These late outgrowth cells lost the ability to form myeloid colonies (data not shown), suggesting they had become terminally differentiated.
The SMC-like outgrowth cells showed a significant change in Ca 2ϩ influx in response to membrane depolarization by high potassium buffer similarly to differentiated aortic SMC (Figure 2A ). This calcium influx was completely inhibited by L-type calcium channel blocker, nifedipine. Additionally, SMC outgrowth cells possessed the ability to contract in response to SM agonist angiotensin II ( Figure 2B , video online).
Discussion
Little is known about specific cell surface markers that define putative SM progenitor cell populations in BM. Previous studies have used either whole mononuclear cells or BMC populations to derive cells that acquire SMC immunophenotype in vitro. [5] [6] [7] [8] We have recently shown that CX 3 CR1 is stably expressed over multiple passages in high-proliferativepotential SM outgrowth cells from human blood. 2 CX 3 CR1 ϩ BMC have previously been identified as an immediate progenitor to macrophage/dendritic cells, 9 and we have shown that high proliferative potential SM outgrowth cells are also of myeloid lineage. 2 It is therefore conceivable that CX 3 CR1 marks a myeloid and putative SMC progenitor population. Bidirectional plasticity previously has been suggested for mature macrophages and SMC in vitro. 10, 11 Uniquely, in the current study we showed that late outgrowth SM-like cells derived from highly enriched CX 3 CR1 BMC possessed functionalities associated inter-alia with differentiated SMC. These included myofilament/cytoskeletal organization, calcium signaling, and contraction in response to the agonist angiotensin II. L-type high-voltage gated calcium channels on vascular SMC have previously been shown not only to mediate excitation-contraction coupling but also to directly correlate with the state of differentiation and SMspecific protein expression in these cells. 12 Here, we show that SMC-like outgrowth excitability is also inhibited by the calcium channel blocker nifedipine. Finally, adoptive transfer experiments ( Figure IV ) support the potential for in vivo SMC differentiation of CX 3 CR1 BMC in the context of vascular injury and are consistent with recent data by our group using chimeric mice with BM transplantations. 13
Conclusion
It must be noted that in this study SMC progenitors are not shown at a single cell level and are in fact heterogeneous, generating SMC-like and monocyte/macrophage-like subsets. This is a potential limitation on future studies of mechanistic control and may have implications for subsequent human studies. In conclusion, our data provide evidence that a CX 3 CR1 BMC population enriches and generates, at very low frequency, differentiated SM-like cells and suggests a chemokine receptor target for future studies dissecting the role of BM progenitor cells in vascular biology. Future characterization of specific CX 3 CR1 ϩ cell subsets may be necessary for therapeutic targeting in the context of vascular disease.
